Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report.

Authors

Yosuke Kakiuchi, Miyu Imai

Published in

Internal medicine (Tokyo, Japan). Jul 11, 2026. Epub Jul 11, 2026.

Abstract

B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations are rare (1-2%) in invasive mucinous adenocarcinoma (IMA). The therapeutic effect of dabrafenib combined with trametinib in IMA with BRAF mutations remains unknown. An 82-year-old man with a BRAF V600E mutation was diagnosed with mixed invasive mucinous and nonmucinous adenocarcinoma of the lung (cT4N1M1a, stage IVA) and he was treated with dabrafenib plus trametinib. The treatment effect continued for 14 months, suggesting that combined dabrafenib and trametinib as targeted therapy is a potential treatment option for BRAF V600E mutation-positive mixed invasive mucinous and nonmucinous adenocarcinoma of the lung.

PMID:
42438024
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.